ArticleProceedings of the National Academy of Sciences of the United States of America2015
Drug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Synthesis of Mesoporous Silica Using the Sol-Gel Approach: Adjusting Architecture and Composition for Novel Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Advances in high throughput cell culture technologies for therapeutic screening and biological discovery applications.Bioengineering & translational medicine · 2024Review
- Article
- FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through β‑catenin nuclear localization.Oncology reports · 2023Article
- Microcrater-Arrayed Chemiluminescence Cell Chip to Boost Anti-Cancer Drug Administration in Zebrafish Tumor Xenograft Model.Biology · 2021Article
- GRAS-microparticle microarrays identify dendritic cell tolerogenic marker-inducing formulations.Lab on a chip · 2021Article
- Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.Advances in experimental medicine and biology · 2021Article
- Article
- A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments.Scientific reports · 2019Article
- Epithelial-mesenchymal transition of cancer cells using bioengineered hybrid scaffold composed of hydrogel/3D-fibrous framework.Scientific reports · 2019Article
- One-Step Generation of a Drug-Releasing Hydrogel Microarray-On-A-Chip for Large-Scale Sequential Drug Combination Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Rapid phenotyping of cancer stem cells using multichannel nanosensor arrays.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- Combinatorial drug delivery approaches for immunomodulation.Advanced drug delivery reviews · 2017Review
- ParaStamp and Its Applications to Cell Patterning, Drug Synergy Screening, and Rewritable Devices for Droplet Storage.Advanced biosystems · 2017Article
- A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation.Journal of materials chemistry. B · 2016Article
- Molecular diagnosis: Implications for ophthalmology.Progress in retinal and eye research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
A new paradigm in oncology establishes a spectrum of tumorigenic potential across the heterogeneous phenotypes within a tumor. The cancer stem cell hypothesis postulates that a minute fraction of cells within a tumor, termed cancer stem cells (CSCs), have a tumor-initiating capacity that propels tumor growth. An application of this discovery is to target this critical cell population using chemotherapy; however, the process of isolating these cells is arduous, and the rarity of CSCs makes it difficult to test potential drug candidates in a robust fashion, particularly for individual patients. To address the challenge of screening drug libraries on patient-derived populations of rare cells, such as CSCs, we have developed a drug-eluting microarray, a miniaturized platform onto which a minimal quantity of cells can adhere and be exposed to unique treatment conditions. Hundreds of drug-loaded polymer islands acting as drug depots colocalized with adherent cells are surrounded by a nonfouling background, creating isolated culture environments on a solid substrate. Significant results can be obtained by testing <6% of the cells required for a typical 96-well plate. Reliability was demonstrated by an average coefficient of variation of 14% between all of the microarrays and 13% between identical conditions within a single microarray. Using the drug-eluting array, colorectal CSCs isolated from two patients exhibited unique responses to drug combinations when cultured on the drug-eluting microarray, highlighting the potential as a prognostic tool to identify personalized chemotherapeutic regimens targeting CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.